AR015744A1 - Uso de dexmedetomidina para sedacion en terapia intensiva - Google Patents

Uso de dexmedetomidina para sedacion en terapia intensiva

Info

Publication number
AR015744A1
AR015744A1 ARP990101414A ARP990101414A AR015744A1 AR 015744 A1 AR015744 A1 AR 015744A1 AR P990101414 A ARP990101414 A AR P990101414A AR P990101414 A ARP990101414 A AR P990101414A AR 015744 A1 AR015744 A1 AR 015744A1
Authority
AR
Argentina
Prior art keywords
dexmedetomidine
sedation
pharmaceutically acceptable
acceptable salt
intensive therapy
Prior art date
Application number
ARP990101414A
Other languages
English (en)
Original Assignee
Orion Corp
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26763325&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR015744(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orion Corp, Abbott Lab filed Critical Orion Corp
Publication of AR015744A1 publication Critical patent/AR015744A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Uso de la dexmedetomidina o de una sal farmacéuticamente aceptable de la misma para sedacion en terapia intensiva. De preferencia, la dexmedetomidina o unasal farmacéuticamente aceptable de la misma es administrada en una cantidad determinada para lograr una concentracion en plasma de 0,1 mg/ml a 2 ng/ml ytambién preferentemente, la dexmedetomidina o su sal es el unico agente activo administrado. Uso de la dexmedetomidina o de una sal farmacéuticamente aceptablede la misma en la fabricacion de un medicamento para su uso en la sedacion en terapia intensiva.
ARP990101414A 1998-04-01 1999-03-30 Uso de dexmedetomidina para sedacion en terapia intensiva AR015744A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8028798P 1998-04-01 1998-04-01
US11094498P 1998-12-04 1998-12-04

Publications (1)

Publication Number Publication Date
AR015744A1 true AR015744A1 (es) 2001-05-16

Family

ID=26763325

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990101414A AR015744A1 (es) 1998-04-01 1999-03-30 Uso de dexmedetomidina para sedacion en terapia intensiva

Country Status (27)

Country Link
EP (1) EP1069893B1 (es)
JP (1) JP4606581B2 (es)
KR (1) KR20010034728A (es)
CN (1) CN1168441C (es)
AR (1) AR015744A1 (es)
AT (1) ATE347359T1 (es)
AU (1) AU754484B2 (es)
BG (1) BG64540B1 (es)
BR (1) BR9909872A (es)
CA (1) CA2326339C (es)
CZ (1) CZ301013B6 (es)
DE (1) DE69934305T2 (es)
DK (1) DK1069893T3 (es)
EA (1) EA005524B1 (es)
ES (1) ES2278441T3 (es)
GB (1) GB2352972B (es)
HU (1) HU229162B1 (es)
IL (1) IL138416A (es)
NO (1) NO329194B1 (es)
NZ (1) NZ507203A (es)
PL (1) PL192517B1 (es)
PT (1) PT1069893E (es)
SI (1) SI1069893T1 (es)
SK (1) SK286160B6 (es)
TR (1) TR200002837T2 (es)
TW (1) TW552136B (es)
WO (1) WO1999049854A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU778522B2 (en) 1999-10-29 2004-12-09 Orion Corporation Treatment or prevention of hypotension and shock
MXPA04009703A (es) * 2002-04-08 2004-12-13 Guilford Pharm Inc Composiciones farmaceuticas que contienen promedicamentos solubles en agua de propofol y metodoss para administrar los mismos.
US7141597B2 (en) * 2003-09-12 2006-11-28 Allergan, Inc. Nonsedating α-2 agonists
US20060058700A1 (en) * 2004-08-26 2006-03-16 Marro Dominic P Patient sedation monitor
JP2010504359A (ja) 2006-09-20 2010-02-12 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 局部麻酔および／または疼痛緩和のための、揮発性麻酔剤を送達するための方法
CN102014961B (zh) 2008-01-22 2017-10-13 得克萨斯大学体系董事会 用于局部麻醉和/或疼痛缓解的含有萃取溶剂的挥发性麻醉剂组合物
AU2010248776B2 (en) * 2009-05-15 2013-06-06 Baudax Bio, Inc. Sublingual dexmedetomidine compositions and methods of use thereof
DE102009050016A1 (de) 2009-05-27 2011-05-05 Modine Manufacturing Co., Racine Wärmeübertragereinheit
US20130096170A1 (en) * 2011-10-14 2013-04-18 Hospira, Inc. Methods of treating pediatric patients using dexmedetomidine
PE20142314A1 (es) 2011-12-11 2015-01-23 Recro Pharma Inc Composiciones intranasales de dexmedetomidina y metodos de uso de ellas
US8242158B1 (en) * 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation
JP5921928B2 (ja) * 2012-03-28 2016-05-24 テルモ株式会社 既希釈デクスメデトミジン製剤
CA2884926C (en) * 2012-10-15 2021-09-21 Orion Corporation A veterinary method of alleviating noise aversion
KR101831536B1 (ko) 2013-07-24 2018-04-04 아이-테크 에이비 표면의 해양 바이오파울링 억제제로서 거울상 이성질체 레보메데토미딘의 용도
EP3054935B1 (en) * 2013-10-07 2020-12-09 Teikoku Pharma USA, Inc. Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions
CN105764496B (zh) 2013-10-07 2020-09-25 帝国制药美国公司 用于经皮递送非镇静量的右旋美托咪啶的方法和组合物
CA2924231C (en) 2013-10-07 2018-04-03 Teikoku Pharma Usa, Inc. Dexmedetomidine transdermal delivery devices and methods for using the same
CN113975273B (zh) * 2020-07-27 2023-07-11 宜昌人福药业有限责任公司 一种抗焦虑用纳米混悬鼻腔喷雾剂及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2101114B (en) * 1981-07-10 1985-05-22 Farmos Group Ltd Substituted imidazole derivatives and their preparation and use
FI844786A0 (fi) * 1984-12-04 1984-12-04 Farmos Oy Terapeutiskt utnyttjbar foerening.
GB2206880B (en) * 1987-07-16 1991-04-24 Farmos Oy Optical isomers of an imidazole derivative
US5344840A (en) * 1988-02-29 1994-09-06 Orion-Yhtyma Oy 4-substituted imidazole derivatives useful in perioperative care
GB2215206B (en) * 1988-02-29 1991-07-03 Farmos Oy 4-substituted imidazole derivatives useful in perioperative care
US5217718A (en) * 1989-08-18 1993-06-08 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5124157A (en) * 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
FI894911A0 (fi) * 1989-10-17 1989-10-17 Farmos Oy En terapeutiskt vaerdefull foerening.
GB2281206A (en) * 1993-08-25 1995-03-01 Orion Yhtymae Oy Use of dexmedetomidine

Also Published As

Publication number Publication date
WO1999049854A3 (en) 1999-11-18
DE69934305D1 (de) 2007-01-18
EP1069893B1 (en) 2006-12-06
BG64540B1 (bg) 2005-07-29
CA2326339A1 (en) 1999-10-07
BR9909872A (pt) 2007-11-20
CN1295473A (zh) 2001-05-16
CN1168441C (zh) 2004-09-29
PL192517B1 (pl) 2006-10-31
JP4606581B2 (ja) 2011-01-05
EA005524B1 (ru) 2005-04-28
CZ20003484A3 (cs) 2002-01-16
IL138416A0 (en) 2001-10-31
ATE347359T1 (de) 2006-12-15
DE69934305T2 (de) 2007-07-12
NZ507203A (en) 2003-03-28
EA200001010A1 (ru) 2001-02-26
IL138416A (en) 2005-07-25
HUP0101498A1 (hu) 2002-03-28
NO329194B1 (no) 2010-09-13
JP2002509880A (ja) 2002-04-02
TR200002837T2 (tr) 2001-01-22
CZ301013B6 (cs) 2009-10-14
SI1069893T1 (sl) 2007-04-30
BG104797A (en) 2001-07-31
DK1069893T3 (da) 2007-03-19
GB0024932D0 (en) 2000-11-29
HUP0101498A3 (en) 2002-06-28
HU229162B1 (hu) 2013-09-30
AU3149499A (en) 1999-10-18
SK14362000A3 (sk) 2002-03-05
SK286160B6 (sk) 2008-04-07
NO20004931D0 (no) 2000-09-29
ES2278441T3 (es) 2007-08-01
WO1999049854A2 (en) 1999-10-07
KR20010034728A (ko) 2001-04-25
NO20004931L (no) 2000-09-29
CA2326339C (en) 2008-12-23
GB2352972A (en) 2001-02-14
PL343553A1 (en) 2001-08-27
PT1069893E (pt) 2007-01-31
TW552136B (en) 2003-09-11
AU754484B2 (en) 2002-11-14
GB2352972B (en) 2003-05-21
EP1069893A2 (en) 2001-01-24

Similar Documents

Publication Publication Date Title
AR015744A1 (es) Uso de dexmedetomidina para sedacion en terapia intensiva
CO5271759A1 (es) Formulacion en solucion que contiene una mezcla de disolventes
AR059324A2 (es) Una forma solida de dosificacion oral
BR0109779A (pt) Soluções moleculares hidrofìlicas dispersas de carvedilol
BR0107869A (pt) Composições farmacêuticas eletrogiradas
BR0207024A (pt) Medicamento com ação inicial rápida para o tratamento de disfunção sexual
CO5261582A1 (es) Composiciones de valdecoxib
ES2188782T3 (es) Formulaciones farmaceuticas que contienen darifenacina.
BR0316082A (pt) Métodos de tratar ou prevenir e de controlar uma doença mieloproliferative, de reduzir ou evitar um efeito adverso associado com a administração de um segundo agente ativo em um paciente sofrendo de uma doença mieloproliferativa e de aumentar a eficácia terapêutica de um tratamento de doenças mieloproliferativa, composição farmacêutica e kit
DE69826644D1 (de) Topische pharmazeutische zusammensetzung, enthaltend einen cholinergischen wirkstoff oder einen kalziumkanalblocker
CO4970819A1 (es) Tratamiento de disfuncion sexual femenina en una hembra humana
BRPI0415007A (pt) método para tratar, prevenir, modificar ou administrar dor, e, composição farmacêutica
CL2008003938A1 (es) Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden de estres postraumatico (divisional sol. 1799-00).
BRPI0108435B8 (pt) formulação e uso de entecavir de baixa dose
KR960700061A (ko) 니코틴 의존상태 치료를 위한 약리학적 제형 (pharmaceutical composition for treating nicotine dependence)
ES2721899T3 (es) Composiciones farmacéuticas que comprenden fentanilo para su administración intranasal
JP2002528502A5 (es)
BR0010082A (pt) Método para melhorar a eficácia de um agente antitumoral
BR0109515A (pt) Derivados da apomorfina e métodos para seu uso
AR019699A1 (es) Composicion farmaceutica para el tratamiento de disfuncion de la evacuacion y uso de la misma para la preparacion de un agente terapeutico
JP2004501939A5 (es)
MX9205568A (es) Composicion farmaceutica que contiene cantidades de 5-amino-1beta-d-ribofuranosil-imidazol-4-carboxamida.
AR035946A1 (es) Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos
ES2142430T3 (es) Compuestos farmaceuticos en forma de gel conteniendo sales de sulfato de condroitina apropiadas para administracion oral.
AR041069A1 (es) Composicion de tolterodina liquida oral

Legal Events

Date Code Title Description
FB Suspension of granting procedure